Praxis Precision Medicines, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Praxis Precision Medicines, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
2.45
8.55
0
Research and development
29.6
45
120
155
86.8
152
267
General and administrative
6.23
17
47.1
59.9
42.1
56.3
59.1
Operating expenses
35.8
62
167
215
129
209
326
Operating income
-35.8
-62
-167
-215
-126
-200
-326
Interest income
0.19
0.14
0.27
0.96
Other non-operating income
0.19
0.14
0.27
0.96
3.1
17.3
22.9
Pre-tax income
-35.6
-61.8
-167
-123
-183
-303
Income tax
-0.08
-0.01
0
0.47
Net income
-35.5
-61.8
-167
-214
-123
-183
-303
EBITDA
-35.8
-61.9
-167
-215
-126
-200
-326
EPS, basic
-399.29
-117.99
-59.14
-69.65
-18.69
-10.21
-13.48
EPS, diluted
-399.29
-117.99
-59.14
-69.65
-18.69
-10.21
-13.48
Shares, basic (weighted)
0.1
0.6
2.83
3.07
6.59
17.9
22.5
Shares, diluted (weighted)
0.1
0.6
2.83
3.07
6.59
17.9
22.5
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
44.8
297
139
61.6
81.3
215
357
Short-term investments
106
38.9
0
177
242
Other current assets
0.68
5.72
11.5
10.4
3.58
11.8
11.6
Total current assets
45.5
302
287
111
84.9
404
611
Property, plant and equipment
0.13
0.08
1.21
0.97
0.59
0.23
0.15
Lease right-of-use assets
1.45
0.75
3.65
2.9
2.06
1.13
0.09
Intangible assets
0
Long-term investments
31.5
0
77
327
Other non-current assets
0.62
0.02
0.47
0.42
0.42
0.42
0
Total assets
47.7
303
293
115
87.9
483
938
Accounts payable
2.67
4.09
10.8
14.7
5.82
12.5
24.6
Accrued liabilities
3.46
10.9
26.8
15.9
7.42
23.8
35
Deferred revenue
0
2.82
1.39
0
Total current liabilities
6.82
15.7
38.4
34.3
15.7
37.6
59.8
Lease liabilities
0.76
0
3.5
2.5
1.37
0.11
0
Total liabilities
7.58
15.7
41.9
39
18.3
37.7
59.8
Paid-in capital
0
437
568
607
724
1,282
2,018
Retained earnings
-81
-150
-317
-531
-654
-837
-1,140
Other comprehensive income
0
-0.18
-0.17
0
0.65
0.56
Shareholders' equity
-81
287
251
76.1
69.7
445
878
Total equity
-81
287
251
76.1
69.7
445
878
Total liabilities and equity
47.7
303
293
115
87.9
483
938
Shares outstanding
0.11
2.55
3.02
3.29
8.79
19.4
25.2
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-35.5
-61.8
-167
-214
-123
-183
-303
Depreciation and amortization
0.04
0.05
0.18
0.42
0.43
0.36
0.14
Stock-based compensation
0.67
5.21
22.7
28.6
24.9
41.4
33.9
Change in payables
-0.84
0.96
7.27
3.89
-8.86
6.71
12.1
Cash from operations
-33.4
-52.6
-125
-185
-111
-132
-249
Capital expenditures
-0.1
0
-1.05
-0.44
-0.05
0
-0.06
Purchases of investments
0
-164
-83
0
-372
-624
Sales and maturities of investments
0
24.7
180
39
123
313
Cash from investing
-0.1
0
-141
96.9
39
-248
-311
Stock issued
0
0
98.4
0
Cash from financing
60.4
304
108
10.5
91.9
514
702
Net change in cash
26.9
252
-157
-77.7
19.7
134
142
Free cash flow
-33.5
-52.6
-126
-185
-111
-132
-249
Income taxes paid
0.22
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $280.78 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-25.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-24.4%
Net income / average total assets.
Return on invested capital (ROIC)
-34.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
97.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
126.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
25.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
94.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
101.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
25.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
25.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
94.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
106.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
15.7x
Current assets / current liabilities.
Quick ratio
15.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
15.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$10.48
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$10.47
Cash from operations / diluted weighted shares.
Book value per share
$48.04
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
5.85x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.85x
Market cap / tangible book value, when positive.
FCF yield
-3.9%
Free cash flow / market cap.
Earnings yield
-4.3%
Net income / market cap (the inverse of P/E).
What was Praxis Precision Medicines, Inc.'s revenue in fiscal 2025?
Praxis Precision Medicines, Inc. reported revenue of $0.0 for fiscal 2025, 100% lower than the year before.
Was Praxis Precision Medicines, Inc. profitable in fiscal 2025?
No. It reported a net loss of $303.3M.
How much free cash flow did Praxis Precision Medicines, Inc. generate in fiscal 2025?
Cash from operations of $249.1M minus capital expenditures of $56.0K left free cash flow of -$249.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.